Samk & brichny, let’s propose that the BP insiders or MM/hedge funds have recently & reluctantly decided that a2-73 may actually be IMPROVING/STABILIZING CNS disease patients and that the professionals at Ariana would NOT have spent 12 months creating baseless graphs/charts and pk/pd analysis reflecting same.
That maybe Anavex & Ariana recently just provided evidence of Alzheimer’s patients IMPROVING as long as their blood concentration level of the compound was HIGH.
And that Anavex having previously shown preclinical efficacy in 10 different CNS indications further supports this thesis.
And that the upcoming 7 presentations over the next 12-24 days by 10 different presenters (some being independent 3rd party researchers) on 5 different CNS indications may provide rapid revelations of compelling efficacy to the investment/scientific communities.
Have the pharma giants and those with a vested interest in the status quo possibly become concerned that a small cap biotech will soon provide physicians & patients with the 1st compound to stop or reverse Alzheimer’s progression? (Isn’t that what slides 25-30 seem to be telling us from Ariana’s analysis and slides recently?)
How do market makers / hedge funds and power brokers of a MULTIBILLION dollar industry treat smallcap biotech companies that threaten to move their cheese?
I’m not sure frankly. But MIGHT they influence pharma analysts, and entrenched plaque/tau protein researchers or biotech media/press to discount, disparage, cast doubt, not cover, give zero press, employ online trolls, enlist twitter/motley fool attacks, play games with a thinly-traded low volume stock price?
Is that even conceivably possible?
Some lecture here that it’s crazy talk to believe that there could be dark forces at work in the capital markets when the SOC and multi billions are at risk. Hopefully they’re 100% right.
What I do know, however, is that there’s a ton of shares short and there’s looming efficacy news events that could prove game changing. Couple that with low float and 75% stubborn retail/insider ownership, and this MAY help to explain the constant drumbeat of negative postings online, and the curiously low 200 million current market cap.
